FHCC
MCID: FBR086
MIFTS: 61

Fibrolamellar Carcinoma (FHCC)

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Fibrolamellar Carcinoma

MalaCards integrated aliases for Fibrolamellar Carcinoma:

Name: Fibrolamellar Carcinoma 12 52 15 17
Fibrolamellar Hepatocellular Carcinoma 12 52 58 43 71
Fibrolamellar Hepatocarcinoma 52 58
Fhcc 52 58
Eosinophilic Hepatocellular Carcinoma with Lamellar Fibrosis 52
Polygonal Cell Hepatocellular Carcinoma with Fibrous Stroma 52
Hepatocellular Carcinoma with Increased Stromal Fibrosis 52
Hepatocellular Carcinoma, Fibrolamellar 12
Eosinophilic Glassy Cell Hepatoma 52
Fibrolamellar Oncocytic Hepatoma 52
Oncocytic Hepatocellular Tumor 12
Fl-Hcc 52

Characteristics:

Orphanet epidemiological data:

58
fibrolamellar hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: <1/1000000 (United States); Age of onset: Adolescent,Adult;

Classifications:

Orphanet: 58  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:5015
MeSH 43 C537258
NCIt 49 C4131
SNOMED-CT 67 15619004 253018005
ICD10 via Orphanet 33 C22.0
UMLS via Orphanet 72 C0334287
Orphanet 58 ORPHA401920
UMLS 71 C0334287

Summaries for Fibrolamellar Carcinoma

NIH Rare Diseases : 52 Fibrolamellar carcinoma (FLC) is a rare form of liver cancer which is generally diagnosed in adolescents and young adults (before age 40). Many people with early FLC have no signs or symptoms of the condition. When present, symptoms are often nonspecific (i.e. abdominal pain, weight loss, malaise ) and blamed on other, more common conditions. The exact underlying cause of FLC is poorly understood. Unlike other forms of liver cancer, FLC typically occurs in the absence of underlying liver inflammation or scarring; thus, specific risk factors for this condition remain unidentified. FLC is typically treated with surgical resection .

MalaCards based summary : Fibrolamellar Carcinoma, also known as fibrolamellar hepatocellular carcinoma, is related to mixed fibrolamellar hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and has symptoms including fever, abdominal pain and icterus. An important gene associated with Fibrolamellar Carcinoma is PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha), and among its related pathways/superpathways are Developmental Biology and PI3K-Akt signaling pathway. The drugs Everolimus and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A hepatocellular carcinoma characterized microscopically by laminated fibrous layers interspersed between the tumour cells. The polygonal, deeply eosinophilic tumor cells arise in non-cirrhotic livers.

Wikipedia : 74 Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that... more...

Related Diseases for Fibrolamellar Carcinoma

Diseases related to Fibrolamellar Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 251)
# Related Disease Score Top Affiliating Genes
1 mixed fibrolamellar hepatocellular carcinoma 32.7 PRKACA KRT7 KRT19 DNAJB1
2 intrahepatic cholangiocarcinoma 31.1 KRT7 KRT19 FGFR2 AFP
3 pancreatoblastoma 30.8 SYP NTS AFP
4 cholangiocarcinoma 30.6 KRT8 KRT7 KRT19 FGFR2 CCKBR AFP
5 cholangitis, primary sclerosing 30.5 NR0B2 KRT7 KRT19 AFP
6 sclerosing hepatic carcinoma 30.5 KRT19 AFP
7 pancreatic cancer 29.3 NTS MIR375 KRT8 KRT7 KRT19 GAST
8 ovary neuroendocrine neoplasm 10.7 SYP KRT7
9 fgfr craniosynostosis syndromes 10.6 FGFR2 FGFR1
10 mucinous adenofibroma 10.6 SYP KRT7
11 hepatocellular carcinoma 10.6
12 small cell carcinoma of the bladder 10.6 SYP KRT7
13 endolymphatic sac tumor 10.6 KRT8 KRT7
14 auditory system benign neoplasm 10.6 SYP KRT7
15 pancreatic serous cystadenocarcinoma 10.6 SYP KRT7
16 plagiocephaly 10.6 FGFR2 FGFR1
17 vaginal tubulovillous adenoma 10.6 SYP KRT7
18 urinary bladder small cell neuroendocrine carcinoma 10.6 SYP KRT7
19 subareolar duct papillomatosis 10.6 KRT8 KRT7
20 ureter small cell carcinoma 10.6 SYP KRT7
21 nipple benign neoplasm 10.6 KRT8 KRT7
22 middle ear adenoma 10.6 SYP KRT7
23 benign breast adenomyoepithelioma 10.6 KRT8 KRT7
24 jejunal neoplasm 10.6 SYP KRT7
25 krukenberg carcinoma 10.6 SYP KRT7
26 rosette-forming glioneuronal tumor 10.6 SYP FGFR1
27 gallbladder small cell carcinoma 10.6 SYP KRT7
28 gastrointestinal neuroendocrine benign tumor 10.6 SYP GAST
29 sensory organ benign neoplasm 10.6 SYP KRT7
30 mixed ductal-endocrine carcinoma 10.6 SYP GAST
31 ovarian large-cell neuroendocrine carcinoma 10.6 SYP KRT7
32 appendix adenocarcinoma 10.6 SYP KRT7
33 mucinous ovarian cystadenoma 10.6 KRT7 GAST
34 primary hepatic neuroendocrine carcinoma 10.6 VIM SYP
35 glomangiomyoma 10.6 VIM SYP
36 nodular hidradenoma 10.6 VIM KRT7
37 papillary tumor of the pineal region 10.6 VIM SYP
38 rete testis neoplasm 10.6 KRT7 AFP
39 syndromic craniosynostosis 10.6 FGFR2 FGFR1
40 wolffian duct adenocarcinoma 10.6 KRT7 FGFR2
41 rete testis adenocarcinoma 10.6 KRT7 AFP
42 benign metastasizing leiomyoma 10.6 VIM KRT7
43 testicular spermatocytic seminoma 10.6 NR0B2 FGFR2
44 synovium neoplasm 10.6 KRT8 KRT7
45 ureteral benign neoplasm 10.6 SYP KRT7
46 pineal region teratoma 10.5 SYP AFP
47 gastric neuroendocrine neoplasm 10.5 SYP GAST
48 thymus sarcomatoid carcinoma 10.5 SYP AFP
49 ovarian endodermal sinus tumor 10.5 KRT7 AFP
50 epididymal neoplasm 10.5 KRT7 AFP

Graphical network of the top 20 diseases related to Fibrolamellar Carcinoma:



Diseases related to Fibrolamellar Carcinoma

Symptoms & Phenotypes for Fibrolamellar Carcinoma

UMLS symptoms related to Fibrolamellar Carcinoma:


fever, abdominal pain, icterus, malaise

GenomeRNAi Phenotypes related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-114 9.28 AFP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.28 AFP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.28 AFP
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-6 9.28 KRT8
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.28 AFP
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.28 AFP
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.28 KRT7 KRT8
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.28 AFP

MGI Mouse Phenotypes related to Fibrolamellar Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.24 AFP CCKBR FGFR1 FGFR2 GAST ITGA1
2 cardiovascular system MP:0005385 10.22 CCKBR FGFR1 FGFR2 ITGA1 ITGAV ITGB4
3 growth/size/body region MP:0005378 10.18 CCKBR FGFR1 FGFR2 ITGA1 ITGAV ITGB4
4 digestive/alimentary MP:0005381 10.16 CCKBR FGFR1 FGFR2 GAST ITGAV ITGB4
5 endocrine/exocrine gland MP:0005379 10.13 AFP CCKBR FGFR1 FGFR2 GAST ITGAV
6 immune system MP:0005387 10.06 CCKBR FGFR1 FGFR2 GAST ITGA1 ITGAV
7 liver/biliary system MP:0005370 9.86 AFP CCKBR FGFR2 KRT19 KRT8 NR0B2
8 neoplasm MP:0002006 9.7 AFP FGFR2 GAST ITGAV KRT19 PRKACA
9 nervous system MP:0003631 9.7 CCKBR FGFR1 FGFR2 ITGAV ITGB4 KRT19
10 renal/urinary system MP:0005367 9.28 CCKBR FGFR1 FGFR2 ITGA1 ITGAV ITGB4

Drugs & Therapeutics for Fibrolamellar Carcinoma

Drugs for Fibrolamellar Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
2
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
3
Leuprolide Approved, Investigational Phase 2 53714-56-0 657181 3911
4
nivolumab Approved Phase 1, Phase 2 946414-94-4
5
Fluorouracil Approved Phase 1, Phase 2 51-21-8 3385
6
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
7 Estrogen Antagonists Phase 2
8 Estrogen Receptor Antagonists Phase 2
9 Estrogens Phase 2
10 Aromatase Inhibitors Phase 2
11 interferons Phase 1, Phase 2
12 Antineoplastic Agents, Immunological Phase 1, Phase 2
13 Interferon alpha-2 Phase 1, Phase 2
14 Interferon-alpha Phase 1, Phase 2
15 Antiviral Agents Phase 1, Phase 2
16 Antimetabolites Phase 1, Phase 2
17 Protein Kinase Inhibitors Phase 2
18 Angiogenesis Inhibitors Phase 2
19
Ipilimumab Approved Phase 1 477202-00-9
20 Immunoglobulins Phase 1
21 Antibodies Phase 1
22 Vaccines Phase 1
23 Antibodies, Blocking Phase 1
24 Poly ICLC Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase 2, Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (FLC) Completed NCT02234986 Phase 2 ENMD-2076
2 A Randomized Three Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Active, not recruiting NCT01642186 Phase 2 everolimus;letrozole plus leuprolide;combination of everolimus, letrozole and leuprolide
3 A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma Not yet recruiting NCT04380545 Phase 1, Phase 2 Fluorouracil
4 A Multicenter National Phase II Open Study Coupled With Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Hepatocellular Carcinoma. Terminated NCT01215565 Phase 2 Sutent
5 Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Fibrolamellar or Non-fibrolamellar Hepatocellular Carcinoma (HCC) Including Fibrolamellar HCC Withdrawn NCT02702960 Phase 2 Cyclophosphamide;Mesna;Filgrastim;Tacrolimus;mycophenolate mofetil;Prednisone;Antithymocyte globulin;fludarabine
6 Phase II Study of Oral Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Withdrawn NCT04025567 Phase 2 vancomycin
7 A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma Recruiting NCT04248569 Phase 1 DNAJB1-PRKACA peptide vaccine;Nivolumab;Ipilimumab
8 A Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma Withdrawn NCT03748927
9 Molecular Analysis of Liver Cancer Withdrawn NCT00899002

Search NIH Clinical Center for Fibrolamellar Carcinoma

Cochrane evidence based reviews: fibrolamellar hepatocellular carcinoma

Genetic Tests for Fibrolamellar Carcinoma

Anatomical Context for Fibrolamellar Carcinoma

MalaCards organs/tissues related to Fibrolamellar Carcinoma:

40
Liver, Lymph Node, Bone Marrow, Bone, Lung, Testes, Pancreas

Publications for Fibrolamellar Carcinoma

Articles related to Fibrolamellar Carcinoma:

(show top 50) (show all 467)
# Title Authors PMID Year
1
ASO Author Reflections: Fibrolamellar Hepatocellular Carcinoma and Alpha-Fetoprotein. 61
32189170 2020
2
Fibrolamellar Carcinoma With Predominantly Pseudoglandular Architecture: A Potential Diagnostic Pitfall. 61
32508199 2020
3
Fibrolamellar Carcinoma. 61
32498783 2020
4
Fibrolamellar Carcinoma: Novel Insights into a Rare Subtype. 61
32056041 2020
5
Elevated Serum α-Fetoprotein is Associated with Abbreviated Survival for Patients with Fibrolamellar Hepatocellular Carcinoma Who Undergo a Curative Resection. 61
31925595 2020
6
A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. 61
32400000 2020
7
In situ hybridisation for albumin RNA in paediatric liver cancers compared with common immunohistochemical markers. 61
32471888 2020
8
Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience. 61
32397993 2020
9
BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. 61
31862487 2020
10
Fibrolamellar hepatocellular carcinoma-related hyperammonemic encephalopathy: Up to now and next steps. 61
31679315 2020
11
Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities. 61
32294439 2020
12
DnaJ-PKAc fusion induces liver inflammation in a zebrafish model of fibrolamellar carcinoma. 61
32102783 2020
13
DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. 61
31676785 2020
14
Acute Onset Hyperammonemic Encephalopathy Related to Fibrolamellar Carcinoma: Another One Bites the Dust. 61
32014302 2020
15
Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. 61
32154962 2020
16
Cytoreductive Surgery and HIPEC for Recurrent Fibrolamellar Hepatocellular Carcinoma with Peritoneal Carcinomatosis. 61
30989576 2020
17
Imaging Features of Fibrolamellar Hepatocellular Carcinoma with Contrast-Enhanced Ultrasound. 61
32102105 2020
18
Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma. 61
32051207 2020
19
Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study. 61
32052215 2020
20
DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient. 61
31736218 2020
21
Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database. 61
32014928 2020
22
Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma. 61
31669305 2020
23
Clavicle tumor as an initial manifestation of fibrolamellar hepatocellular carcinoma. 61
31677896 2020
24
Hyperammonemic encephalopathy: An unusual presentation of fibrolamellar hepatocellular carcinoma. 61
31422648 2020
25
Fibrolamellar hepatocellular carcinoma with paraneoplastic neuropsychiatric manifestations. 61
31965677 2020
26
MDM4 expression in fibrolamellar hepatocellular carcinoma. 61
31322272 2019
27
Emerging Roles of GLI-Similar Krüppel-like Zinc Finger Transcription Factors in Leukemia and Other Cancers. 61
31474360 2019
28
Inhibition of the chimeric DnaJ-PKAc enzyme by endogenous inhibitor proteins. 61
30938854 2019
29
A prognostic nomogram for patients with resected fibrolamellar hepatocellular carcinoma. 61
31489303 2019
30
Neurotensin as a source of cyclic AMP and co-mitogen in fibrolamellar hepatocellular carcinoma. 61
31489118 2019
31
Hepatocellular Carcinoma of Fibrolamellar Type in an Adolescent: Case Report and Literature Review. 61
31602376 2019
32
Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review. 61
31183212 2019
33
Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. 61
31183207 2019
34
Spontaneous Rupture of Fibrolamellar Variant Hepatocellular Carcinoma. 61
31236158 2019
35
Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. 61
30902819 2019
36
An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma. 61
31063128 2019
37
Structures of the PKA RIα Holoenzyme with the FLHCC Driver J-PKAcα or Wild-Type PKAcα. 61
30905674 2019
38
Progression after Immunotherapy for Fibrolamellar Carcinoma. 61
31312648 2019
39
Update on the pathology of liver neoplasms. 61
30597357 2019
40
[Hepatocellular carcinomas and their mimics]. 61
30706100 2019
41
MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma. 61
30763770 2019
42
Road map for fibrolamellar carcinoma: progress and goals of a diversified approach. 61
30951568 2019
43
Hardened Liver Due to Fibrolamellar Hepatocellular Carcinoma. 61
29505903 2019
44
State-of-the-art MR Imaging of Uncommon Hepatocellular Tumours: Fibrolamellar Hepatocellular Carcinoma and Combined Hepatocellularcholangiocarcinoma. 61
31989878 2019
45
Fibrolamellar Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Multidisciplinary Therapy. 61
30101933 2018
46
Acquired ornithine transcarbamylase deficiency in pediatric and adolescent patients with fibrolamellar hepatocellular carcinoma. 61
30094907 2018
47
Hepatic Sclerosing Hemangioma Simulating Gallbladder Carcinoma: A Rare Case. 61
30564006 2018
48
Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases. 61
29948061 2018
49
Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion. 61
29222914 2018
50
Management of fibrolamellar hepatocellular carcinoma. 61
30395718 2018

Variations for Fibrolamellar Carcinoma

Cosmic variations for Fibrolamellar Carcinoma:

9 (show top 50) (show all 15431)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 6
2 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 6
3 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 6
4 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 6
5 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 6
6 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 6
7 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 6
8 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 6
9 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 6
10 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 6
11 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 6
12 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 6
13 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 6
14 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 6
15 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 6
16 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 6
17 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 6
18 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 6
19 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 6
20 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 6
21 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 6
22 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 6
23 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 6
24 COSM92703312 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 6
25 COSM92032561 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221= 14:67807621-67807621 6
26 COSM84360265 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.1979+14C>A p.? 5:32395145-32395145 6
27 COSM84362097 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 6
28 COSM85178149 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 6
29 COSM87884183 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 6
30 COSM127392053 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 6
31 COSM149268658 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 6
32 COSM149328017 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 6
33 COSM149281099 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 6
34 COSM144309108 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 6
35 COSM87420403 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 6
36 COSM98996636 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 6
37 COSM92255466 ZC3H15 liver,NS,carcinoma,hepatocellular carcinoma c.*55T>G p.? 2:186508788-186508788 6
38 COSM85044193 ZC3H14 liver,NS,carcinoma,hepatocellular carcinoma c.*10873G>A p.? 14:88622624-88622624 6
39 COSM106743522 ZBTB7B liver,NS,carcinoma,hepatocellular carcinoma c.*635G>C p.? 1:155017320-155017320 6
40 COSM93795261 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 6
41 COSM103188148 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 6
42 COSM91488114 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 6
43 COSM95291738 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 6
44 COSM107993551 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2383A>G p.I795V 8:80519295-80519295 6
45 COSM107993152 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2208A>G p.T736= 8:80518852-80518852 6
46 COSM86073785 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 6
47 COSM142300159 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1580A>G p.N527S 8:63187582-63187582 6
48 COSM90849676 YOD1 liver,NS,carcinoma,hepatocellular carcinoma c.*157T>C p.? 1:207048863-207048863 6
49 COSM90620829 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 6
50 COSM86902201 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167= 3:183722100-183722100 6

Expression for Fibrolamellar Carcinoma

Search GEO for disease gene expression data for Fibrolamellar Carcinoma.

Pathways for Fibrolamellar Carcinoma

Pathways related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 PRKACA KRT8 KRT7 KRT19 ITGAV ITGA1
2
Show member pathways
12.81 PRKACA ITGB4 ITGAV ITGA1 FGFR2 FGFR1
3
Show member pathways
12.79 ITGB4 ITGAV ITGA1 FGFR2 FGFR1
4
Show member pathways
12.62 PRKACA ITGB4 ITGAV ITGA1 FGFR2 FGFR1
5 12.42 ITGB4 ITGAV ITGA1 FGFR2 FGFR1
6 12.25 VIM KRT8 KRT7 KRT19 ITGAV
7
Show member pathways
12.23 ITGB4 ITGAV ITGA1 FGFR2 FGFR1
8
Show member pathways
12.08 PRKACA ITGB4 ITGAV ITGA1
9 11.7 ITGAV FGFR2 FGFR1
10 11.67 ITGB4 ITGAV ITGA1
11 11.62 VIM SYP FGFR1
12
Show member pathways
11.62 YAP1 ITGB4 ITGAV ITGA1 FGFR2 FGFR1
13
Show member pathways
11.59 VIM KRT8 KRT7 KRT19
14 11.33 VIM KRT8 ITGB4 ITGAV
15 11.21 ITGB4 ITGAV ITGA1
16 10.79 PRKACA ITGB4 ITGAV ITGA1 FGFR2 FGFR1
17 10.7 VIM ITGB4 ITGAV ITGA1 FGFR2 FGFR1
18 10.18 GAST CCKBR

GO Terms for Fibrolamellar Carcinoma

Cellular components related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.61 VIM PRKACA KRT8 KRT7 KRT19 ITGB4
2 intermediate filament GO:0005882 9.46 VIM KRT8 KRT7 KRT19
3 integrin complex GO:0008305 8.8 ITGB4 ITGAV ITGA1

Biological processes related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.93 VIM KRT8 KRT7 KRT19 ITGAV
2 positive regulation of cell proliferation GO:0008284 9.92 YAP1 ITGAV FGFR2 FGFR1 CCKBR
3 integrin-mediated signaling pathway GO:0007229 9.73 ITGB4 ITGAV ITGA1
4 cell-matrix adhesion GO:0007160 9.72 ITGB4 ITGAV ITGA1
5 regulation of osteoblast differentiation GO:0045667 9.57 PRKACA FGFR2
6 mesodermal cell differentiation GO:0048333 9.51 ITGB4 FGFR2
7 branching involved in salivary gland morphogenesis GO:0060445 9.49 FGFR2 FGFR1
8 mesenchymal cell differentiation GO:0048762 9.48 FGFR2 FGFR1
9 lung-associated mesenchyme development GO:0060484 9.46 FGFR2 FGFR1
10 paraxial mesoderm development GO:0048339 9.43 YAP1 FGFR1
11 positive regulation of phospholipase activity GO:0010518 9.4 FGFR2 FGFR1
12 bud elongation involved in lung branching GO:0060449 9.37 YAP1 FGFR2
13 positive regulation of cardiac muscle cell proliferation GO:0060045 9.33 YAP1 FGFR2 FGFR1
14 cell differentiation involved in embryonic placenta development GO:0060706 9.32 KRT8 KRT19
15 orbitofrontal cortex development GO:0021769 9.26 FGFR2 FGFR1
16 ventricular zone neuroblast division GO:0021847 8.96 FGFR2 FGFR1
17 fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development GO:0035607 8.62 FGFR2 FGFR1

Molecular functions related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 YAP1 VIM PRKACA NTS NR0B2 LINC00473
2 insulin-like growth factor I binding GO:0031994 9.32 ITGB4 ITGAV
3 neuregulin binding GO:0038132 9.16 ITGB4 ITGAV
4 fibroblast growth factor-activated receptor activity GO:0005007 8.96 FGFR2 FGFR1
5 fibroblast growth factor binding GO:0017134 8.8 ITGAV FGFR2 FGFR1

Sources for Fibrolamellar Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....